Codexis Announced It Has Entered Into An Agreement With Aldevron; Whereby Aldevron Will Acquire A Global Exclusive License To Codexis' Codex HiCap RNA Polymerase
Portfolio Pulse from Benzinga Newsdesk
Codexis has entered into an agreement granting Aldevron a global exclusive license to its Codex HiCap RNA Polymerase. Aldevron gains manufacturing and commercialization rights, while Codexis will receive payments for technical and commercial milestones, as well as sales-based royalties. Both companies will collaborate to ensure a smooth transition for customers.
December 13, 2023 | 9:08 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Codexis has licensed its Codex HiCap RNA Polymerase to Aldevron, which will handle manufacturing and commercialization. Codexis is set to receive milestone payments and royalties, indicating a potential new revenue stream.
The agreement with Aldevron is likely to be seen as a positive development for Codexis, as it not only validates the company's technology but also opens up a new and potentially significant source of revenue through milestone payments and royalties. This could be perceived positively by investors and may lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100